FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2317999314> ?p ?o ?g. }

• W2317999314 endingPage "546" @default.
• W2317999314 startingPage "540" @default.
• W2317999314 abstract "Introduction Patients with severe hemophilia have circulating blood coagulation factor VIII (hemophilia A) or factor IX (hemophilia B) levels below 1% of normal due to a genetic defect in the respective X-linked gene. The resulting bleeding disorder is characterized by spontaneous joint bleeds or, in a more life-threatening situation, into critical closed spaces, such as the intracranial or retroperitoneal space. Current treatment for hemophilia is based on intravenous infusions of clotting factor concentrates. These can be episode-based in response to bleeds (which does not prevent ongoing tissue damage nor the risk of a life-threatening bleed) or prophylactic (an expensive and not always practical alternative). The goal of a gene-based therapy is to introduce a functional clotting factor gene into a patient in order to provide a continuous supply of factor levels above 1%.1,2 Clinical endpoints for the efficacy of potential gene therapy trials for hemophilia are, therefore, well-defined and unequivocal. The relatively small size of the factor IX coding sequence (1.4 kb) and the fact that a number of cell types other than hepatocytes (which normally synthesize factor IX) are capable of producing biologically-active factor IX have contributed to the development of hemophilia B into an important model for the treatment of genetic diseases by gene therapy. The factor IX gene can be incorporated into a variety of vector systems. Various target tissues can be chosen for gene transfer as long as the secreted factor IX reaches the circulation and tight regulation of transgene expression is not required.3 Possibly most important in research on gene therapy for coagulation factor deficiencies, and genetic disorders in general, is the availability of a large animal model with severe disease. In this case, it is the well-characterized hemophilia B dogs maintained at the University of North Carolina at Chapel Hill. The animals contain a point-mutation in the portion of the factor IX gene encoding the catalytic domain. This mutation results in an absence of circulating factor IX antigen and, consequently, severe hemophilia B that closely mimics the human disease.4 Gene therapy strategies for hemophilia B have typically established a method of gene transfer, resulting in expression of factor IX in mice, and subsequently, attempted scale-up to the dog model. These investigations have established experiments in the hemophilic dog model as a critical step for the assessment of the efficacy of gene therapy protocols showing initial promise in mice. For example, reimplantation of primary myoblasts that had been transduced ex vivo with a retrovirus was successful in mice, but not in the canine model.5 Adenoviral gene transfer, characterized by varying success in mice, depending on the strain and dose used, has persistently resulted in high, but transient expression following intravenous infusion into dogs.6,7 Cellular immune responses and hepatotoxicity have limited the expression of factor IX from adenoviral vectors to just a few weeks. Repeat administration of the vector was complicated by the induction of neutralizing antibodies to viral particles in injected animals following the first administration. Retroviral gene transfer to hepatocytes was successful in long-term expression of factor IX in hemophilia B dogs but required a partial hepatectomy prior to infusion of the vector through the portal vein. The resulting expression levels were no higher than 0.1% of normal human factor IX levels.8" @default.
• W2317999314 created "2016-06-24" @default.
• W2317999314 creator A5060779925 @default.
• W2317999314 creator A5086755266 @default.
• W2317999314 date "1999-01-01" @default.
• W2317999314 modified "2023-10-15" @default.
• W2317999314 title "Adeno-Associated Virus-Mediated Gene Transfer of Factor IX for Treatment of Hemophilia B by Gene Therapy" @default.
• W2317999314 cites W1255418244 @default.
• W2317999314 cites W1487084354 @default.
• W2317999314 cites W1519383882 @default.
• W2317999314 cites W1527938269 @default.
• W2317999314 cites W1588659566 @default.
• W2317999314 cites W1616824889 @default.
• W2317999314 cites W1702771419 @default.
• W2317999314 cites W1756236371 @default.
• W2317999314 cites W1942870285 @default.
• W2317999314 cites W1965172479 @default.
• W2317999314 cites W1974877896 @default.
• W2317999314 cites W1978519692 @default.
• W2317999314 cites W1979746830 @default.
• W2317999314 cites W1980111025 @default.
• W2317999314 cites W1980283599 @default.
• W2317999314 cites W1998290936 @default.
• W2317999314 cites W2007854533 @default.
• W2317999314 cites W2009991379 @default.
• W2317999314 cites W2010347101 @default.
• W2317999314 cites W2014010760 @default.
• W2317999314 cites W2014952919 @default.
• W2317999314 cites W2015433718 @default.
• W2317999314 cites W2016782363 @default.
• W2317999314 cites W2026854040 @default.
• W2317999314 cites W2044286471 @default.
• W2317999314 cites W2049592320 @default.
• W2317999314 cites W2060216304 @default.
• W2317999314 cites W2089745978 @default.
• W2317999314 cites W2091357864 @default.
• W2317999314 cites W2093444214 @default.
• W2317999314 cites W2106378095 @default.
• W2317999314 cites W2110329858 @default.
• W2317999314 cites W2117198730 @default.
• W2317999314 cites W2130506552 @default.
• W2317999314 cites W2140523898 @default.
• W2317999314 cites W2143836588 @default.
• W2317999314 cites W2148223197 @default.
• W2317999314 cites W2155898643 @default.
• W2317999314 cites W2166031247 @default.
• W2317999314 cites W2177849941 @default.
• W2317999314 cites W2337290468 @default.
• W2317999314 cites W2395841498 @default.
• W2317999314 cites W2412855262 @default.
• W2317999314 cites W2784070057 @default.
• W2317999314 cites W3128294301 @default.
• W2317999314 cites W67249329 @default.
• W2317999314 cites W2084017165 @default.
• W2317999314 doi "https://doi.org/10.1055/s-0037-1615877" @default.
• W2317999314 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10605748" @default.
• W2317999314 hasPublicationYear "1999" @default.
• W2317999314 type Work @default.
• W2317999314 sameAs 2317999314 @default.
• W2317999314 citedByCount "31" @default.
• W2317999314 countsByYear W23179993142012 @default.
• W2317999314 countsByYear W23179993142013 @default.
• W2317999314 countsByYear W23179993142020 @default.
• W2317999314 countsByYear W23179993142022 @default.
• W2317999314 crossrefType "journal-article" @default.
• W2317999314 hasAuthorship W2317999314A5060779925 @default.
• W2317999314 hasAuthorship W2317999314A5086755266 @default.
• W2317999314 hasConcept C104317684 @default.
• W2317999314 hasConcept C111599444 @default.
• W2317999314 hasConcept C126322002 @default.
• W2317999314 hasConcept C186738567 @default.
• W2317999314 hasConcept C203014093 @default.
• W2317999314 hasConcept C2778107364 @default.
• W2317999314 hasConcept C2778382381 @default.
• W2317999314 hasConcept C2779936836 @default.
• W2317999314 hasConcept C2781221834 @default.
• W2317999314 hasConcept C2992139802 @default.
• W2317999314 hasConcept C40767141 @default.
• W2317999314 hasConcept C54355233 @default.
• W2317999314 hasConcept C71924100 @default.
• W2317999314 hasConcept C86803240 @default.
• W2317999314 hasConcept C92087593 @default.
• W2317999314 hasConceptScore W2317999314C104317684 @default.
• W2317999314 hasConceptScore W2317999314C111599444 @default.
• W2317999314 hasConceptScore W2317999314C126322002 @default.
• W2317999314 hasConceptScore W2317999314C186738567 @default.
• W2317999314 hasConceptScore W2317999314C203014093 @default.
• W2317999314 hasConceptScore W2317999314C2778107364 @default.
• W2317999314 hasConceptScore W2317999314C2778382381 @default.
• W2317999314 hasConceptScore W2317999314C2779936836 @default.
• W2317999314 hasConceptScore W2317999314C2781221834 @default.
• W2317999314 hasConceptScore W2317999314C2992139802 @default.
• W2317999314 hasConceptScore W2317999314C40767141 @default.
• W2317999314 hasConceptScore W2317999314C54355233 @default.
• W2317999314 hasConceptScore W2317999314C71924100 @default.
• W2317999314 hasConceptScore W2317999314C86803240 @default.
• W2317999314 hasConceptScore W2317999314C92087593 @default.
• W2317999314 hasIssue "08" @default.

• next